Molecular hydrogen: phase III and long-term clinical evidence

Evidence audit dated September 19, 2026. Scope: molecular hydrogen (H₂), including hydrogen-rich water, hydrogen-generating tablets, inhaled gas, hydrogen-containing intravenous solutions, dialysate, and organ-preservation solutions.